Have a personal or library account? Click to login
CLEC5A Knockdown Reduces Oxidative Stress and Inflammation Caused by Lipopolysaccharide in Renal Tubular Epithelial Cells via the NF-κB/NLRP3 Signaling Pathway Cover

CLEC5A Knockdown Reduces Oxidative Stress and Inflammation Caused by Lipopolysaccharide in Renal Tubular Epithelial Cells via the NF-κB/NLRP3 Signaling Pathway

Open Access
|Oct 2025

Abstract

Sepsis-related acute kidney injury (S-AKI) is a severe condition characterized by rapid onset and high mortality. Thus, identifying effective treatments for S-AKI is of critical importance. Lipopolysaccharide (LPS) was used to activate HK-2 cells to mimic S-AKI in vitro. Lentiviral transfection was performed to knock down C-type lectin domain family 5 member A (CLEC5A) expression, and protein immunoblotting was used to detect changes in CLEC5A expression. Cell damage was evaluated using the cell counting kit-8 (CCK-8) and lactate dehydrogenase (LDH) kit, cellular inflammatory factor levels were determined using the enzyme-linked immunosorbent assay (ELISA), and oxidative stress signs were detected using the kit. Western blotting was used to detect the expression of NF-κB/NLRP3 (NLR family, pyrin domain-containing protein 3) pathway, and NF-κB activator was used to detect whether knockdown of CLEC5A acts through the NF-κB/NLRP3 pathway. LPS stimulated the expression of CLEC5A in HK-2 cells. Knockdown of CLEC5A could inhibit the LPS-induced decrease in HK-2 cell viability and increased LDH release. Knockdown of CLEC5A could inhibit the LPS-induced increase in HK-2 cell release of inflammatory factors. Knockdown of CLEC5A could inhibit LPS-induced oxidative stress. CLEC5A knockdown can prevent the NF-κB/NLRP3 signaling pathway from being activated, and NF-κB activation can undo the effects of CLEC5A knockdown. Knockdown of CLEC5A can ameliorate renal tubular damage and lessen inflammation and oxidative stress via reducing NF-κB/NLRP3 activation.

Language: English
Submitted on: May 22, 2025
Accepted on: Aug 13, 2025
Published on: Oct 31, 2025
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2025 Zunjiang Chen, Chengfeng Pan, Xuexiu Chen, Shangli Xie, Yuechuan Lin, Xingken Fan, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 74 (2026): Issue 1 (January 2026)